rs7753394 — TNFAIP3

The 6q23 Regulatory Switch — A Tag SNP in the TNFAIP3 Neighborhood

A key principle in genomics is that most disease-associated variants found by genome-wide association studies are not located in protein-coding sequences — they sit in the regulatory landscape between genes, tuning how much of a critical protein gets made. rs7753394 exemplifies this principle. It resides on chromosome 6 in the intergenic stretch between OLIG3¹¹ OLIG3
Oligodendrocyte lineage transcription factor 3 — a transcription factor with roles in neural development; not itself directly implicated in autoimmune disease and TNFAIP3²² TNFAIP3
Tumor necrosis factor alpha-induced protein 3 — the gene encoding A20, the immune system's master brake on NF-kB inflammatory signaling, approximately 100 kb upstream of the TNFAIP3 transcription start site. It was captured in the landmark 2007 Wellcome Trust Case Control Consortium GWAS³³ Wellcome Trust Case Control Consortium GWAS
The WTCCC enrolled 14,000 cases across 7 common diseases (bipolar disorder, coronary artery disease, Crohn's disease, rheumatoid arthritis, type 1 and 2 diabetes, and hypertension) and 3,000 shared controls in the largest genetic association study of its time and has since been typed in studies of ulcerative colitis, Crohn's disease, and inflammatory pathway genetics.

The Mechanism

rs7753394 is a tag SNP⁴⁴ tag SNP
A tag SNP is a variant in high linkage disequilibrium with nearby variants; it "tags" the same haplotype block and serves as a proxy for the causal variant in that chromosomal region in the 6q23 regulatory zone. This zone has been characterized as a region of active chromatin that physically loops to contact the TNFAIP3 promoter, influencing how much A20 protein the cell can produce in response to immune signals. Multiple independent studies have now demonstrated that regulatory variants in this region act as repressors of TNFAIP3 transcription⁵⁵ repressors of TNFAIP3 transcription
In vitro luciferase reporter assays show that 6q23 intergenic SNP alleles bound by NF-kB subunits with reduced avidity result in weaker enhancer-promoter looping and less A20 mRNA; risk haplotypes express lower A20 levels than protective haplotypes.

A20, encoded by TNFAIP3, is a dual-function ubiquitin-editing enzyme⁶⁶ dual-function ubiquitin-editing enzyme
A20 has two catalytic domains: an N-terminal OTU deubiquitinase that removes activating K63-linked ubiquitin chains from TRAF6, NEMO, and RIP1; and a C-terminal ZnF4 domain that adds inhibitory K48-linked ubiquitin chains targeting these signaling proteins for proteasomal degradation that terminates NF-kB inflammatory signaling once an immune response has served its purpose. Without sufficient A20, the inflammatory cascade persists beyond its useful window — sustaining cytokine production, prolonging immune cell activation, and raising the probability that the immune system loses self-tolerance. This is the core mechanism linking 6q23 regulatory variants to autoimmune disease risk across multiple conditions.

The 6q23 locus contains three statistically independent association signals for rheumatoid arthritis — rs6920220 (the primary risk signal), rs13207033 (a protective signal), and rs5029937 (an additional risk signal within TNFAIP3 intron 2). rs7753394, located ~100 kb upstream, tags the broader regulatory haplotype structure of this locus and was specifically co-typed in IBD genetics studies to assess whether the 6q23 regulatory signal extends to ulcerative colitis and Crohn's disease as well as to RA and SLE.

The Evidence

rs7753394 was included in the WTCCC 2007 study⁷⁷ WTCCC 2007 study
A landmark genome-wide association study enrolling 14,000 cases across 7 common diseases including Crohn's disease, rheumatoid arthritis, and type 1 diabetes, which established the 6q23 intergenic region as a genuine autoimmune susceptibility locus. The subsequent Fisher et al. 2008 study⁸⁸ Fisher et al. 2008 study
Nature Genetics study identifying ulcerative colitis loci including ECM1 and five shared with Crohn's disease specifically tested rs7753394 in the 6q23 region as part of a cross-disease replication panel — UC testing did not find significant association (p = 0.61), indicating the 6q23 signal for UC does not extend to this specific tag SNP, though other variants at the locus (rs6920220, rs13207033) do associate with IBD susceptibility through TNFAIP3 haploinsufficiency.

The regulatory mechanism by which 6q23 intergenic variants influence TNFAIP3 was formally demonstrated by functional reporter assays⁹⁹ functional reporter assays
Luciferase reporter gene assays showed that three of five intergenic 6q23 SNPs tested (rs6920220, rs6933404, rs6927172) exhibited allele-dependent repressor activity on TNFAIP3 promoter activity; EMSA data confirmed differential transcription factor binding. Cells carrying risk haplotypes at the 6q23 locus express measurably lower TNFAIP3 mRNA and A20 protein compared to non-risk haplotype carriers — providing a direct path from variant to reduced NF-kB braking capacity to autoimmune disease risk.

The Eleftherohorinou 2009 pathway analysis¹⁰¹⁰ Eleftherohorinou 2009 pathway analysis
PLoS ONE study analyzing GWAS data for three inflammatory diseases (Crohn's disease, RA, type 1 diabetes) using canonical pathway enrichment; identified multiple NF-kB pathway variants including those at the TNFAIP3/6q23 locus as cross-disease signals further reinforced that the 6q23 region's NF-kB regulatory machinery influences risk across inflammatory conditions, not just RA, consistent with the pan-autoimmune nature of A20 biology.

Practical Implications

For CC carriers (two copies of the C allele at rs7753394), the clinical relevance depends on the broader 6q23 haplotype context — particularly the genotype at rs6920220 (the primary risk variant) and rs13207033 (the primary protective variant). CC at rs7753394 combined with risk alleles at companion 6q23 SNPs indicates reduced A20 expression capacity, which can be partially compensated by interventions that directly modulate NF-kB activity. The VITAL randomized trial¹¹¹¹ VITAL randomized trial
A 5-year RCT with 25,871 adults assigned to vitamin D3 2,000 IU/day, omega-3 1 g/day, both, or placebo; vitamin D reduced incident autoimmune disease by 22% (HR 0.78, P=0.05), omega-3 by 15% established that both vitamin D3 and omega-3 fatty acids reduce autoimmune disease incidence through direct NF-kB pathway modulation — making them the most evidence-backed compensatory interventions for carriers of 6q23 risk haplotypes.

Interactions

rs7753394 is part of the broader 6q23 regulatory haplotype that includes rs6920220, rs13207033, and rs5029937. The three-SNP combination model shows that carriers of both risk alleles at rs6920220 and rs5029937 who also lack the protective rs13207033 A allele face the highest combined RA risk at this locus (OR 1.86, 95% CI 1.51–2.29). rs7753394 genotype adds tag-SNP information about this haplotype structure. The TNFAIP3 coding variant rs2230926 (F127C) operates through a distinct mechanism — impaired A20 enzymatic activity rather than altered expression — and is independently relevant to autoimmune risk.